A reduction-responsive amphiphilic core-shell micelle for miriplatin delivery was prepared and evaluated. A pyrene-terminated poly(2-(dimethylamino) ethyl acrylate) was synthesized through reversible addition-fragmentation chain transfer polymerization with 4-cyano-4-(ethylthiocarbonothioylthio) pentanoic acid as reversible addition-fragmentation chain transfer reagent and further modified by 2,2 0 -dithiodiethanol and 1-pyrenebutyric acid. Self-assembled blank micelles and drug-loaded micelles were obtained by dialysis method, and the particle size was proved to be about 40 nm with narrow dispersity by dynamic laser light scattering. Morphology results showed that blank micelles and drug-loaded micelles were spherical nanoparticles confirmed by transmission electron microscope, and the critical micelle concentration was as low as 6.09 mg/mL via pyrene fluorescence probe method. The reductive sensitivity of disulfide bond in BMs was further verified by changes in particle size, pyrene fluorescence intensity ratio (I 338 /I 333 ), and morphology after treatment by dithiothreitol. Moreover, drug release rate in vitro of drug-loaded micelles was evaluated and the results suggested that this amphiphilic pyrene-modified poly(2-(dimethylamino) ethyl acrylate) can be used as reduction-triggered controlled release drug delivery carrier for hydrophobic drug.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide and chemotherapy is the major therapeutic tool for it. 1, 2 However, traditional chemical preparations show limited efficiency in hepatic tumor treatment, because these agents distribute evenly within human body through circulatory system. Consequently, the liver has a comparatively low drug concentration, leading to a low therapeutic effect, whereas other organs are likely to be impaired by the toxic effects of these anticancer drugs. Additionally, poor stability of some chemotherapy reagents may also reduce their anti-neoplastic effect. Therefore, a stable drug delivery system that can enhance the chemosensitivity of tumor cells but reduce the side effects to the normal cells or tissues is needed.
Miriplatin is a kind of the third generation of platinumbased anticancer drugs, with enhanced hydrophobicity and reduced adverse reaction compared to other platinum-based agents, and it has been applied in the transcatheter arterial chemoembolization (TACE) therapy of HCC in clinic. [3] [4] [5] [6] [7] [8] [9] [10] However, this administration route exists tremendous defects, which limits its clinical application. 11 Consequently, targeting carriers of such agents have attracted increasing attention as efficient drug delivery systems, which could increase efficacy and decrease systemic side effects.
Nano-sized polymeric micelles are assemblies of synthetic polymers and have been actively studied as carriers of drugs and contrast agents since the 1980s. [12] [13] [14] [15] Polymeric micelles could provide many valuable characteristics such as biostability, biodegradability, biocompatibility, drug solubilization. Moreover, polymeric micelles with 10-100 nm could gather in the organization that has permeability of blood vessels, such as tumor, inflammation, or infarction areas, which was named enhanced permeability and retention effect (EPR). The so called EPR effect made polymer micelles to be nature passive targeting carrier. 17 Therefore, polymeric micelles hold a great promising as novel anti-tumor drug carriers.
Radical addition-fragmentation chain transfer (RAFT) polymerization has been widely applied for defined polymer preparation. 18, 19 Compared with other controlled living radical polymerizations, RAFT-mediated polymerizations exhibit several advantages, including the tolerance to a variety of monomer structures and reaction conditions, potential compatibility with aqueous solutions, and narrow molecular weight distribution of the desired polymeric products, [20] [21] [22] particularly in biological applications as it can be performed at ambient temperature in the absence of mental catalysts. 23, 24 In this study, amphiphilic pyrene-modified poly(2-(dimethylamino) ethyl acrylate) (PDMAEA) was synthesized via RAFT polymerization and modified by pyrene with disulfide linkage via esterification, PDMAEA is a pH-sensitive biocompatible polymer (pK b ¼ 6.5) 25 and can self-catalyzed degrade to poly(acrylic acid), which is non-toxic. 26 Then, nano-sized blank micelles (BMs) and miriplatin-loaded micelles (DMs) were prepared by dialysis method. Characterizations of these micelles showed that BMs and DMs exhibited narrow dispersity around 40 nm and also reduction-sensitivity. Drug release properties of DMs were evaluated under simulated blood and intracellular environment in vitro, and results showed that DMs could maintain stability in blood environment but burst release drug in reduction environment. After 24 h, the accumulative rate could reach 80.18%. 
Materials

Reagents
4-Cyano-4-(ethylthiocarbonothioylthio)
pentanoic acid (CEPA), synthesized as reported 27 ; 2,2 0 -Dithiodiethanol (90%), Thermo Fisher Scientific Co., Ltd; 2-(Dimethylamino) ethyl acrylate (DMAEA) (99%), 1-pyrenebutyric acid (99%), pyrene(98%), DL-dithiothreitol (DTT) (99%), Aladding Reagent Co., Ltd; N,N 0 -dicyclohexyl carbodiimide (DCC) (99%), 4-dimethylamino pyridine (DMAP) (99%), Adamas Reagent Co., Ltd; tetrahydrofuran (THF) (AR), methyl cyanides(99.8%), tert-butyl alcohol (CP), methanol (GR), Chinese Medicine Group Chemical Reagents Co., Ltd; ethanol (GR), Tianjin Kermel Chemical Reagent Co., Ltd; n-hexane (AR), Tianjin Fuyu Fine Chemical Co.,Ltd; ethyl acetate(99.5%), Tianjin Yongda Chemical Reagent Co., Ltd; 2,2 0 -azobisisobutyronitrile (AIBN) (98%), 1,4-dioxane(AR), Tianjin Chemical Reagent Co., Ltd.
Experiments and discussions
Synthesis of amphiphilic PDMAEA
As shown in Figure 1 . (2) 2,2 0 -Dithiodiethanol (3.5450 g), DCC (1.6990 g), and DMAP (0.1003 g) were dissolved in THF (2 mL) in a round bottom flask, then CEPA (1.0880 g) in 5 mL THF was added dropwise. The mixture was stirred at room temperature for 48 h and filtered to remove the precipitate. Then, the filtrate was condensed by reduced pressure distillation. Final product was purified by silica gel chromatography using n-hexane/ ethyl acetate (3:2) as the eluent and the 1 HNMR was shown in 
Synthesis of hydroxy terminated RAFT agent
Synthesis of pyrnene terminated RAFT agent (3)
RAFT agent (2) (0.4974 g), DCC (0.4992 g), and DMAP (0.0292 g) were dissolved with THF (4 mL) in a round bottom flask. 1-pyrenebutyric acid (0.4025 g) in 6 mL THF was added dropwise. Then, the mixture was stirred at room temperature for 58 h and filtered to remove the precipitate. The filtrate was condensed under reduced pressure and then subject to silica gel chromatography using n-hexane/ ethyl acetate (5:2) as the eluent to obtain the expected Figure 1 Synthesis route of amphiphilic PDMAEA product. Chemical structure of RAFT agent (3) was confirmed by 1 HNMR (as shown in Figure 2 ). 1 HNMR (600 MHz, CDCl 3 , d): 2.21 (m, 2H, CH 2 CH 2 CH 2 ), 2.49 (t, 2H, CH 2 CH 2 CO), 3.40 (t, 2H, pyrene-CH 2 ), 7.86-8.31 (m, 9H, CH of pyrene).
Synthesis of pyrene-terminated PDMAEA
RAFT(3) (0.0925 g), DMAEA (2.0286 g), and AIBN (0.0080 g) in 1,4-dioxane (2.5 mL) were prepared followed by the deoxygenation with nitrogen for 30 min. Polymerization was carried out at 75 C for 15 h to afford PDMAEA, which was purified by repeated precipitation in n-hexane for three times and then dried under vacuum, as shown in 
Preparation of BMs
A certain amount of PDMAEA (20 mg) was dispersed in 10 mL ultrapure water, then the solutions were treated with ultrasonic probe at 400 W for 30 min at 0 C (pulse on 2.0 s, pulse off 3.0 s) to obtain the BMs solutions (2 mg/mL), as shown in Figure 3 . The micellar solution occurred ''Tyndall effect''.
Characterization of BMs
Critical micelle concentration of BMs. Pyrene fluorescence probe was the most common method to determine the critical micelle concentration (CMC). [28] [29] [30] Briefly, 2 mL of pyrene solution (2 Â 10 À6 moL/L) with acetone as solvent was added into 12 test tubes, respectively. After the acetone was evaporated by water bath at 60 C, 10 mL of BMs solution at different concentrations (from 0.05 mg/mL to 3 mg/mL) was added into the test tubes orderly. The mixture was ultrasonicated for 30 min at room temperature. The fluorescence excitation spectrum of pyrene in the final solution was measured with fluorescence spectrophotometer after 24 h. The emission wavelength was set at 390 nm, and the slit of excitation and emission at 10 nm and 2.5 nm, respectively. Then, the intensity ratios of the excitation wavelength 338 nm and 333 nm in the pyrene emission spectra were calculated. The CMC was obtained from trend changing of the intensity ratios, as shown in Figure 4 . The CMC of BMs was 6.09 mg/mL, which was obtained by tangent method.
The morphological observation of BMs. BMs solution (2 mg/mL) was dropped on a 300 mesh copper grid and kept for 3-5 min, the excess fluid was removed by absorbent paper. Negative staining was performed using 5% aqueous phosphotungstic acid for 30 min before observation with transmission electron microscope (TEM), as shown in Figure 5 . The micelles were regular spherical particles, and their surfaces were smooth and not conglutinated.
Particle size and zeta potential determination of BMs. BMs solution (1 mg/mL) was prepared to measure the particle size and zeta potential by using Malvern Zetasizer Nano ZS90. The sample was measured thrice, as shown in Figure 6 . The micelles have a unimodal size distribution and a small size (mean diameter was 39.68 nm) (a), as well as zeta potential (mean potential was 1.24 mV) (b).
The reductive sensitivity of the disulfide bond test. Preparation of BMs 20 mL (2 mg/mL) was divided into two groups evenly. The experimental group was treated with 10 mM DTT, and both the DTT treated group and untreated group were incubated at 25 C with slight vibration. Particle size and pyrene solubilizing were measured at given time point, and the morphology of the experimental group treated with DTT for 3 h was observed by TEM, as shown in Figure 7 . As reported, DTT is a kind of reductant and 10 mM DTT was equivalent to the high reducing environment in the tumor cells. 31 Results showed that after incubation with 10 mM DTT, fluorescence intensity of pyrene in BMs solution kept reducing, while the untreated group kept invariable, which indicated that BMs showed instability in reduction environment. This could owe to existence of disulfide bond between hydrophilic PDMAEA chains and hydrophobic pyrene core. When treated by 10 mM DTT, disulfide linkage broke and pyrene cores precipitated from aqueous solution, then the compatibilizing effect of pyrene probe disappeared. Morphology observation by TEM also proved that BMs lost their spherical shape and core-shell structure after treated by 10 mM DTT.
Preparation of drug-loaded micelles
Determination of encapsulation efficiency. We adopted the method of microporous membrane filter to determine the EE. DMs were broken by adding organic solvent (90% tert-butyl alcohol and 10% methyl cyanides) under ultrasonic.
After shifting by single factor experiment and orthogonal test by using EE as key index, the optimal prescription craft was obtained: 60 mg of pyrene-modified PDMAEA was dispersed in 15 mL ultrapure water by ultrasonication (400 W, pulse on 2 s, pulse off 3 s) for 30 min, to get the BMs solution (4 mg/mL); a certain amount of miriplatin (5.0 mg) was added to 1.875 mL tert-butyl alcohol: methyl cyanides (9:1) via ultrasonic dissolving, prepared the drug solution. Under the condition of electromagnetic stirring, drug solution was added into the BMs (v/v, 1:8) by drops with a certain speed (v, 1 d/2 s). The mixing solution was stirred for 10 min continuously. Then, it was placed in dialysis bag The morphology observation of DMs. The method was same to BMs, as shown in Figure 8 . The micelles were regular spherical particles, and their surfaces were smooth and not conglutinated.
Particle size and zeta potential determination of drugloaded micelles. The method was same to BMs, as shown in Figure 9 . The DMs have a unimodal size distribution and a small size (mean diameter was 51.5 nm) (a), as well as zeta potential (mean potential was 0.891 mV) (b).
Drug release characteristics of DMs in vitro
Dialysis was used to determine drug release in vitro. 32 To simulate intracellular environment and blood environment, we have prepared 20 mL drug-loaded micellar solution and put it into two groups average. One group added into DTT (a), made its final concentration 10 mM; the other group was untreated (b). Then, the mixture was placed in dialysis bag (MWCO ¼ 1000 Da) and the bag was put in 30 mL of ABS buffer (pH ¼ 5.0) and PBS buffer (pH ¼ 7.4) dialyzing after the seal, respectively. The Miriplatin contents in the dialysate at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 9.0, 12.0, 15.0, 18.0, 21.0, and 24.0 h were determined by high performance liquid chromatography (HPLC), according to the established standard curve (Y ¼ 5833.1X-1235.9, R 2 ¼ 0.9999), drawing the drug cumulative release amount of time curve, as shown in Figure 10 . At 9 h, the drug accumulative rate reaches about 80.18%. In a sense, DMs have favorable drug-loading and reduction-responsive release property.
Conclusion
To achieve the systemic delivery of miriplatin, an amphiphilic pyrene-modified PDMAEA was synthesized with disulfide bond between hydrophilic PDMAEA moities and hydrophobic pyrene. Then, nano-sized micelles, BMs, and drug-loaded micelles (DMs) were obtained by dialysis method. The mean diameter of BMs and DMs were around 40 nm, with a narrow size distribution. Such small size is helpful to avoid reticuloendothelial system (RES) capturing and to accumulate at tumor site via EPR effect. Due to the strong hydrophobicity of pyrene, BMs had a quite low CMC of 6.09 mg/mL which indicated that BMs may have a stable structure in aqueous solution. However, owing to the existence of disulfide bond in BMs and DMs, these micelles exhibited sensitivities to reducing envirionment. At last, drug release characteristics of DMs at simulative intracellular environment (10 mM DTT, pH ¼ 5.0) were tested. It was remarkable that burst release of miriplatin was observed in the first 5 h and then it took about 9 h to reach the final release rate of miriplatin at 80.18%, comparing to 10.4% in PBS. In a sense, it indicated that DMs could exist stable in blood environment but rapid release miriplatin after endocytosis into tumor cells. From the above, we considered this reduction-responsive micelle formed by pyrene-PDMAEA as a potential drug carrier for sustained release of miriplatin.
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